Revenue ₹1,422 Cr (+21% YoY)
0 met · 0 close · 8 missed across 8 tracked promises
View all executive profiles for Ajanta Pharma LtdAjanta Pharma delivered a strong Q4 FY26 with revenue of ₹1,422 crore (+21% YoY) and PAT of ₹267 crore (+18% YoY).
0% promises delivered
Based on 8 tracked promises across 3 quarters
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Quarterly Earnings Timeline
Financial verification status, call summary, sentiment, and management-delivery signals by quarter.
Q4 FY26
15 May 2026
Revenue ₹1,422 Cr (+21% YoY)
Ajanta Pharma delivered a strong Q4 FY26 with revenue of ₹1,422 crore (+21% YoY) and PAT of ₹267 crore (+18% YoY).
bullish
high
4 missed
Read full analysis →
Q3 FY26
10 Feb 2026
Revenue ₹1,375 Cr (+20% YoY)
Ajanta Pharma delivered a strong Q3 FY26 with consolidated revenue of ₹1,375 crore (+20% YoY) and EBITDA of ₹382 crore (+19% YoY), driven by robust US generics (+52% Y...
bullish
high
4 missed
Read full analysis →
Q2 FY26
06 Nov 2025
Revenue ₹1,354 Cr (+14% YoY)
Ajanta Pharma delivered a strong Q2 FY26 with consolidated revenue of ₹1,354 crore (+14% YoY) and PAT of ₹260 crore (+20% YoY).
bullish
high
Scorecard starts after historical backfill
Read full analysis →